Charles River Laboratories International Inc., a Wilmington-based drug research company, reportedly is preparing to acquire a Chinese pharmaceutical contractor for about $1.6 billion. (Full article: 420 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
